Last reviewed · How we verify

Olaparib 200-300 mg BID, daily — Competitive Intelligence Brief

Olaparib 200-300 mg BID, daily (Olaparib 200-300 mg BID, daily) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PARP inhibitor (DNA damage response inhibitor). Area: Oncology.

discontinued PARP inhibitor (DNA damage response inhibitor) PARP1 and PARP2 (poly(ADP-ribose) polymerase enzymes) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Olaparib 200-300 mg BID, daily (Olaparib 200-300 mg BID, daily) — Repare Therapeutics. Olaparib inhibits PARP enzymes to block DNA single-strand break repair, inducing synthetic lethality in BRCA-mutant and HR-deficient cancers.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Olaparib 200-300 mg BID, daily TARGET Olaparib 200-300 mg BID, daily Repare Therapeutics discontinued PARP inhibitor (DNA damage response inhibitor) PARP1 and PARP2 (poly(ADP-ribose) polymerase enzymes)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PARP inhibitor (DNA damage response inhibitor) class)

  1. Repare Therapeutics · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Olaparib 200-300 mg BID, daily — Competitive Intelligence Brief. https://druglandscape.com/ci/olaparib-200-300-mg-bid-daily. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: